Member Info for Bella6532

Around 15% of all breast cancers – over 8,000 cases a year in the UK – are triple negative.

https://breastcancernow.org/about-us/blogs/triple-negative-breast-cancer-explained/

Breast cancer is the most commonly diagnosed cancer in the United States (US), with approximately 280,000 women diagnosed with this malignancy in 2021.

TNBC constitutes approximately 15% of all diagnosed breast cancer cases in the US and is associated with distant metastases, aggressive histology, poorer prognosis, shorter survival, and unresponsiveness to therapy compared to other breast cancer subtypes. Patients with TNBC by definition are not candidates for endocrine therapy or treatment with targeted HER2 agents. Although TNBC responds to neoadjuvant chemotherapy, patients who do not achieve a complete response have a disproportionately high relapse and mortality rate.

TNBC accounts for ~10-15% of all breast cancer cases, with 300 thousand cases reported globally in 2022. Asia leads in incidence followed by Europe, North America, and the rest of the world. 

The global triple-negative breast cancer treatment market size was evaluated at $11 billion in 2022 and is slated to hit $20 billion by the end of 2030

Main players...Novartis AG, Eli Lilly and Company, AstraZeneca PLC, Sanofi S.A., Mylan N.V., Pfizer Inc., F. Hoffman - La Roche Ltd., Celgene Corporation, Bristol-Myers Squibb Company, Johnson & Johnson Drug Type Inc., and others.

Haha..looks like my EMail earlier worked..now updated to include Panmure...let's see if they manage to correct the other boo boos...

'Advisors

Joint Broker and NOMAD – Peel Hunt, 100 Liverpool Street, London, EC2M 2AT.

Joint Broker – Panmure Liberum, 25 Ropemaker Street London EC2Y 9LY.

Auditor – BDO LLP, Newton House, Cambridge Business Park, Cambridge, CB4 0WZ'

Still far too many mistakes/missed updates/omissions on the website...on that page they don't list Panmure as joint broker!!?

Afraid I do think the upcoming webinar will be way above most PIs heads and ever many IIs too.

Who and what are they hoping to get from it?

Any real investors will have direct access and/or been at the recent conference.

If the Finals are issued tomorrow morning then yes it could be an opportunity to answer more pressing issues but without them I don't think they'll be drawn and go off piste. ☹️

Also why the move to Quarterly Updates is this to fall in line with Nazdaq Listing when it happens and what vehicle will used to list...

6pm Thursday...allows for whole of US to be open for business...but does it also allow for Finals to be RNSd at 7am...otherwise it's a bit strange to do just a product webinar prior to Finals.

We also need news/update on Coris sale.

Nasdaq update.

Funding update.

Existing Partnering updates.

Next Pipeline candidate.

Confirmation timescales as already laid out still on target or improved.

FDA approvals/application updates.

And anything else I've forgotten to mention...

'Positive Phase 1 outcomes for AVA6000 not only de-risk the pre|CISION® technology but could also unlock substantial upside via licensing deals or partnerships, given the platform’s broad applicability across roughly 90% of solid tumours that express FAP. Each new pre|CISION candidate (such as AVA6103) builds on the validated mechanism of targeted drug release, giving Avacta a chance to develop differentiated oncology products with enhanced efficacy and safety profiles compared to conventional chemotherapies. However, significant challenges remain: the company must navigate the usual clinical and regulatory hurdles to bring its therapies to market, and it will eventually require additional financing as trials progress. Balancing these opportunities and risks, Avacta enters 2025 with cautious optimism, its innovative approach offers considerable upside potential, albeit tempered by the uncertainties inherent in drug development.'

Hence the need for a Nasdaq Listing to get the funding needed...

https://eqtgroup.com/thinq/early-stage/cancer-cure-breakthrough-will-come-from-early-stage-investments-not-big-pharma

Https://www.labiotech.eu/best-biotech/pharma-biotech-venture-capital-arms/

From and including 23 April..volumes were elevated for 5 consecutive days so it does look like they managed to get rid of most if not all of the shares then...

If Heights want to get access go inside info they'd have to sign an Insider Note...but that would be Avactas call not Heights...such a note would prevent trading in Avacta stock until the info they have access to is released to the wider market.

B2..yes pure fantasy...they would never tell anyone how and when to trade...

,The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.'

Approval = almost $2b each...

Avacta needs approval(s) to get mega deal...right now Investment/partnership is key...

FY Results...Avacta have until end June to issue these. however, they have stated they will be in May...

Last week and this week were obviously not good weeks to publish due to holidays in UK/US.

Last FYR and Interims were both issed on the lat day of the month (30 April 24 & 30 Sept 24)...so they could issue this years FYR on the last day of May (30th)...However, todays' RNS might be a bit of a clue...the new shares are expected to be issued on 14 May!!!...mmm! why the delay...could it be they expect to issue the FYR same day (Wed) or very next day (Thursday) which is often the preferred day of the week used by Avacta.

They usually announce results day a week or so beforehand...so if they should tell us this week if they are going to be next week...or they might consider the foot note in the previous RNS as adequate notice.

Right now it all seems rather fluid....

As I said...2+2 could easily = 5....just a thought

Why sell at these prices if they suspect a rise coming based on good news/financials or they're doing off book deaks...

The whole point about investing in AIM stocks is getting in early doors...that's why the risks are so much greater than investing in tried and tested boring old FTSE stocks.

This is not a market place for the faint of heart...this is Yellowstone/1923/1886 rolled into one...

The new next big thing will be...'cancer treatment without side effects'...

Kong1..'The moment one BP takes an interest , the others will follow immediately.'...

Yep how many times do you see them all dive into 'the next big thing' as soon as one jumps in...herd mentality/fear of being left out...

He might even be on our trial..who knows...

Harry is just one huge spoilt brat...

Good chance Finals RNS will be on 8 May...

Geez you guys are something...did you forget so quickly they had the AACR in the US and then Labour Day holiday and Ester holidays etc etc.. If you're going to publish your Finals and have nothing to hide then do it when everyone is back at work and the markets are focused. Yes, they might also be trying to get the Coris deal over the line too...and they've just had a member of the Audit Committee leave...

Hey ho...not long now...